Proposed Cuts to Indiana Needle Exchange Programs Threaten Public Health Gains
Overview
Indiana's syringe exchange programs have significantly reduced hepatitis C and HIV infections and distributed over 47,000 naloxone doses to reverse overdoses. However, legislative challenges threaten the continuation of these programs beyond July 2026, risking a reversal of public health progress.
Background
Syringe exchange programs were legalized in Indiana in 2015 following a major HIV outbreak linked to injection drug use. These programs provide clean needles, naloxone, and connections to treatment services to reduce the harms associated with drug use. Despite evidence of their effectiveness, some lawmakers and prosecutors oppose their continuation, citing concerns about facilitating drug use. The programs operate in six counties and rely on private funding due to restrictions on taxpayer dollars for syringe purchases.
Data Highlights
Metric
Data
Hepatitis C cases reduction in Marion County
~60% decrease over 5 years
New HIV infections from injection drug use
Decreased (exact percentage not specified)
Naloxone doses distributed (2024-2025)
47,000+
Reported overdose reversals using naloxone
~1,700
Number of syringe exchange users in Indianapolis (past 2 years)
Nearly 6,000
Key Findings
Syringe exchange programs in Indiana have led to a 60% reduction in hepatitis C cases in Marion County over five years.
New HIV infections related to injection drug use have also declined since program implementation.
Over 47,000 naloxone doses were distributed between 2024 and 2025, with approximately 1,700 reported overdose reversals.
Programs provide anonymous, free services but rely on private funding due to state restrictions on taxpayer-funded syringe purchases.
Legislation (Senate Bill 91) aims to extend these programs for another decade but faces opposition from some Republican lawmakers and prosecutors.
Proposed amendments could restrict access by requiring identification and residency proof, potentially limiting program effectiveness.
Clinical Implications
Continuing syringe exchange programs is critical to sustaining reductions in bloodborne infections and preventing opioid overdose deaths through naloxone distribution. Restricting access may increase risky injection behaviors and undermine public health efforts. Healthcare providers should advocate for harm reduction strategies as part of comprehensive addiction treatment and infection prevention.
Conclusion
Indiana's syringe exchange programs have demonstrated clear public health benefits by reducing infections and saving lives through overdose reversals. Legislative support is essential to maintain these gains and provide ongoing harm reduction services to people who use drugs.
References
Mirror Indy/Associated Press/2023 -- Proposed Cuts to Needle Exchange Initiatives in Indiana
